ArticleFrontiers in endocrinology2025
Effect of topical papaverine on parathyroid function preservation after total thyroidectomy: a retrospective cohort study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the effectiveness of locally applied papaverine in preventing hypoparathyroidism after total thyroidectomy and its impact on parathyroid hormone (PTH) recovery. Study design: Retrospective cohort study. Setting: The First Affiliated Hospital of Zhengzhou University. Methods: This single-center retrospective cohort study involved 226 patients who underwent total thyroidectomy at the First Affiliated Hospital of Zhengzhou University from March 2023 to March 2025. The incidence of hypoparathyroidism on postoperative day 1 and the PTH recovery rate within 30 days afterward are compared between patients who received papaverine and those who did not. Data analysis uses the independent samples t-test, the Mann-Whitney U test, and the χ² test. Results: Patients are divided into two groups: those who received intraoperative papaverine (n = 106) and a control group (n = 120). On postoperative day 1, hypoparathyroidism occurs in 40% of the papaverine group and 53% of the control group, respectively. Postoperative PTH recovery rates gradually increase over time, with significantly higher rates in the papaverine group compared to the control group on days 3, 5, and 30. Conclusion: Applying papaverine directly during surgery effectively lowers the risk of early hypoparathyroidism after total thyroidectomy while promoting faster PTH recovery. This method is simple, easy to perform, and has a high safety profile. Future multicenter randomized controlled trials should be conducted to confirm long-term effectiveness and refine the dosing protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.